Glucose Sensors Versus Finger-Prick Testing in Type 2 Diabetes Without Insulin
Compares sensor glucose monitoring with finger-prick testing in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin
Key facts
- Where
- Bialystok, PolandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07919236, who can take part
Where in Poland
- Medical University of Bialystok, Department of Internal Medicine and Metabolic DiseasesBialystok, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of Bialystok
- Trial code
- NCT07919236
- Record updated
- 5 November 2026
- Original description
The aim of the study is to assess the influence of continuous glucose monitoring (CGM) systems on metabolic control and quality of life in people with type 2 diabetes and overweight/obesity who are not treated with insulin. Additionally, the study aims to assess the association between metabolic control of diabetes and markers of early cardiovascular disease, taking into account the impact of CGM use.Read full original descriptionShow less
Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin - the Association With Metabolic Control of Diabetes and Markers of Early Vascular Changes
The aim of the study is to assess the influence of continuous glucose monitoring (CGM) systems on metabolic control and quality of life in people with type 2 diabetes and overweight/obesity who are not treated with insulin. Additionally, the study aims to assess the association between metabolic control of diabetes and markers of early cardiovascular disease, taking into account the impact of CGM use.
Inclusion: Age between 18 and 65 years (both inclusive); Type 2 diabetes diagnosed at least 6 months prior to entering the study; Body mass index ≥25 kg/m2; Diabetes treated with oral medications and/or GLP-1 receptor agonists and/or tirzepatide; No modifications of diabetes treatment in the previous 3 months; HbA1c between 7.5% and 10% (both inclusive); Oral and written informed consent for participation.
Exclusion: Treatment with insulin; Acute infections, acute diabetes complications and/or unplanned hospitalisations in the previous month; Use of steroids or immunosuppressive medications in the previous 3 months; Chemotherapy, radiotherapy, immune therapy in the previous 3 months; Type 1 diabetes, gestational diabetes, other specific types of diabetes; Skin lesions or dermatological conditions preventing proper sensor insertion; HbA1c >10.0%; Previous use of any continuous glucose monitoring system; GFR <30 ml/min; Cognitive impairment and/or other conditions preventing proper use of continuous glucose monitoring system; Lack of consent for the use of continuous glucose monitoring system; Pregnancy and/or breastfeeding.